Sugi Predict
/ Targets
/ SNRK
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to SNRK by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus |
PHASE3 | UNKNOWN |
| I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers |
PHASE1/PHASE2 | NOT_YET_RECRUITING |
| A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas |
PHASE2 | SUSPENDED |
| The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients |
PHASE1/PHASE2 | WITHDRAWN |
| A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRI |
PHASE1/PHASE2 | UNKNOWN |
| Everolimus for Children With Recurrent or Progressive Ependymoma |
PHASE2 | COMPLETED |
| A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H... |
PHASE2 | COMPLETED |
| LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations |
PHASE2 | COMPLETED |
| Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma |
PHASE1 | COMPLETED |
| Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors |
PHASE1 | COMPLETED |
| Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer |
PHASE1 | COMPLETED |
| Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers |
PHASE1 | COMPLETED |
| Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer |
EARLY_PHASE1 | COMPLETED |
| Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 |
EARLY_PHASE1 | COMPLETED |
| Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation |
nan | COMPLETED |
| p-AKT Expression on Clinical Outcomes in Malignant Lymphoma |
nan | COMPLETED |
| Identification of Novel Targetable Kinases in SR-a GvHD |
nan | COMPLETED |
| Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children |
nan | COMPLETED |
| Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) |
nan | COMPLETED |
| Dried Fruit and Postprandial Glycemia Trial |
nan | UNKNOWN |
| Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus |
nan | COMPLETED |
| Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma |
nan | COMPLETED |
| SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases |
nan | NOT_YET_RECRUITING |
| Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients |
nan | COMPLETED |
| Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA |
nan | RECRUITING |
| Metabolic Signalling in Muscle- and Adipose-tissue Following Insulin Withdrawal and Growth Hormone Injection. |
nan | COMPLETED |
| Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients |
nan | RECRUITING |
| Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies |
nan | RECRUITING |
| Protein Intake and Step Reduction in Older Adults |
nan | COMPLETED |
| Genetic-specific Effects of Fructose on Liver Lipogenesis |
nan | COMPLETED |
Related proteins — ESM-2 sequence neighbours (a SNRK binder may also engage these)